CiclopiroxCiclopirox
MedChemExpress (MCE)
HY-B0450
29342-05-0
HOE296b
99.84%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Ciclopirox (HOE296b) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox also has anticancer and anti-inflammatory effect.
Ciclopirox (10 μM, 18 h) inhibits HUVEC proliferation and angiogenesis[4]. Ciclopirox (0-10 μM, 20 h) inhibits deoxyhypusine hydroxylation in HUVECs[4]. Ciclopirox (0-40 μM, 72 h) shows anti-tumor activity in H1299 and 95D cells (decreases cell viability, with IC50s of 11.13 and 4.136 μM respectively), and inhibits cell migration and invasion[5]. Ciclopirox (0-40 μM, 48 h) arrests both H1299 and 95D cells in G1 phase, decreases Cyclin D1 and CDK4 protein level in H1299 and 95D cells[5]. Ciclopirox (0-20 μM) induces cell aerobic glycolysis, impairs mitochondrial functions and enhances the generation of ROS in H1299 and 95D cells[5]. Ciclopirox (0-40 μM, 48 h) activates PERK-dependent ER stress in CRC cells (HCT-8, HCT-8/5-FU, and DLD-1 cells)[6].
Ciclopirox (20 mg/kg, i.p.) reduces tumor size in mouse H1299 xenograft model, and reduces tumor cell proliferation (Ki67 staining) and increases apoptosis (Cleaved-Caspase 3 and Tunel staining)[5]. Ciclopirox (25 mg/kg, p.o., daily) also inhibits tumor growth in human breast cancer MDA-MB231 xenografts in mice[6].
| | | |
| | | | | |
[1]. Niewerth, M., et al., Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother, 2003. 47(6): p. 1805-17. [Content Brief]
[2]. Leem, S.H., et al., The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells, 2003. 15(1): p. 55-61. [Content Brief]
[3]. Ratnavel, R.C., R.A. Squire, and G.C. Boorman, Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat, 2007. 18(2): p. 88-96. [Content Brief]
[4]. Clement PM, et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer. 2002 Aug 1
100(4):491-8. [Content Brief]
[5]. Lu J, et al. Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells. Cell Commun Signal. 2022 Mar 24
20(1):37. [Content Brief]
[6]. Zhou H, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer. 2010 Nov 15
127(10):2467-77. [Content Brief]